Form 4: DiaMedica Therapeutics CFO Scott Kellen Awarded Stock Options

DiaMedica Therapeutics' CFO, Scott Kellen, received stock options for 130,000 common shares on June 1, 2024.

Summary

• On June 1, 2024, Scott Kellen, CFO and Secretary of DiaMedica Therapeutics Inc., was granted stock options to purchase 130,000 common shares.
• The exercise price of these options is $2.90.
• The options vest with respect to 25% of the underlying common shares on June 1, 2025, and the remaining 75% vest quarterly over the following three years, starting September 1, 2025.
• Kellen directly owns 32,290 common shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options with vesting schedules to incentivize their executives.
• The vesting schedule of 25% after one year followed by quarterly vesting is a common structure.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO.
• Employees may see this as a sign of confidence in the company's future.

Key Dates